Bellerophon's board ap­proves liq­ui­da­tion plan, leaves Nas­daq af­ter lay­offs and tri­al fail­ures

Bellerophon Ther­a­peu­tics’ board of di­rec­tors has ap­proved a plan to liq­ui­date the com­pa­ny and now just needs share­hold­er ap­proval to dis­solve af­ter it let go of al­most all of its em­ploy­ees over the sum­mer, ac­cord­ing to SEC fil­ings.

Bellerophon is call­ing a spe­cial meet­ing of the stock­hold­ers to vote on the plan.

In June, the biotech laid off al­most all of its em­ploy­ees and said it would be search­ing for strate­gic al­ter­na­tives af­ter its de­vice for ad­min­is­ter­ing in­haled ni­tric ox­ide, dubbed IN­Opulse, failed a late-stage tri­al for fi­brot­ic in­ter­sti­tial lung dis­ease. The de­vice al­so flunked tri­als in pul­monary ar­te­r­i­al hy­per­ten­sion and Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER